Ajanta Pharma reported excellent performance for Q3 FY26. Revenue from operations increased by 20% to ₹1,375 cr, while Profit After Tax (PAT) rose by 18%. The company’s branded generics business remains a key driver, and the US generics segment experienced substantial growth. The company continues to focus on strategic initiatives to drive future growth and operational efficiency.
Financial Performance Highlights
Ajanta Pharma demonstrated strong financial results for the third quarter of fiscal year 2026. Key highlights include:
- Revenue from operations reached ₹1,375 cr, a 20% increase compared to the previous year’s ₹1,146 cr.
- EBITDA stood at ₹382 cr, up by 19% from ₹321 cr, with an impressive EBITDA margin of 28%.
- Profit after tax (PAT) increased by 18% to ₹274 cr, compared to ₹233 cr in the previous year.
9M FY26 Performance
The company also reported strong results for the nine-month period ending December 31, 2025:
- Revenue from operations grew by 16% to ₹4,031 cr.
- EBITDA rose by 10% to ₹1,061 cr.
- Profit after tax (PAT) increased by 14% to ₹789 cr.
Segment-Wise Performance
The following table shows revenue from each segment:
| Segment | Q3 FY26 (₹ cr) | Q3 FY25 (₹ cr) | Growth (%) | 9M FY26 (₹ cr) | 9M FY25 (₹ cr) | Growth (%) |
| Branded Generics India | ₹409 | ₹345 | 19% | ₹1,250 | ₹1,083 | 15% |
| Branded Generics Asia | ₹288 | ₹316 | -9% | ₹902 | ₹888 | 1% |
| Branded Generics Africa | ₹230 | ₹173 | 33% | ₹679 | ₹617 | 10% |
| US Generic | ₹399 | ₹263 | 52% | ₹1,052 | ₹723 | 46% |
| Africa Institution | ₹41 | ₹33 | 22% | ₹111 | ₹118 | -6% |
Strategic Focus
Ajanta Pharma remains focused on launching new products across markets, increasing market share in existing products, expanding into new countries and therapies, optimizing expenses, and driving digitalization across the organization.
Earnings Call Information
The company will host an earnings conference call on January 30, 2026, at 16:30 hrs IST to discuss the financial results. Details for joining the call are provided in the release.
Source: BSE
